Genome-First Data Suggest Familial Hypercholesterolemia Is Equally Prevalent Across African and European Ancestry Groups, but Underclassified in African Ancestry Patients
Posted inCardiology news Public Health

Genome-First Data Suggest Familial Hypercholesterolemia Is Equally Prevalent Across African and European Ancestry Groups, but Underclassified in African Ancestry Patients

A large multi-cohort genome-first study found similar prevalence of pathogenic FH variants across ancestries, but more VUSs and greater LDL-C and myocardial infarction risk among African ancestry individuals, highlighting likely underclassification and underdiagnosis.
Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
Posted inCardiology news

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor bleeding risk, suggesting a need for cautious clinical application.
ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations
Posted inCardiology news

ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

Recent research reveals that the common ALDH2 rs671 genetic variant significantly enhances platelet activation and arterial thrombosis through aldehyde accumulation, reactive oxygen species, and ACAD10-mediated mitophagy, identifying ALDH2 as a potential novel target for personalized antiplatelet strategies in East Asian patients.